Polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome is a rare plasma dyscrasia without standard treatment. This phase II prospective trial evaluates the safety and response of 12 cycles of low dose lenalidomide (10 mg) plus dexamethasone (Rdex) in patients with newly diagnosed POEMS syndrome. Forty-one patients (28 men) were enrolled and the median age at diagnosis was 49 years (range, 21-70 years). Twentyone patients (46%) achieved complete hematologic response and the neurologic response rate was 95%. The median serum vascular endothelial growth factor (VEGF) declined from 5155 pg/mL (range, 534-14 328 pg/mL) to 832 pg/mL (95-6254 pg/mL) after therapy. The overall VEGF response rate was 83%, and the median time to response was 2 months, with a mean VEGF reduction of 43% at the first month. In terms of clinical response, Rdex substantially relieved extravascular volume overload, organomegaly, and pulmonary hypertension. No treatment-related deaths occurred and no patients suffered from lenalidomide-related grade 3 or above adverse events. After a median follow-up of 34 months, median overall survival (OS) and progression-free survival (PFS) were not reached, with an estimated 3-year OS and PFS of 90% and 75%, respectively. In conclusion, Rdex was active with high hematologic, VEGF and organ response rate and well tolerated for patients with newly diagnosed POEMS syndrome. This trial was registered at www.clinicaltrials.gov as #NCT01816620.
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| I N TR ODU C TI ON
Polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome is a rare plasma cell dyscrasia, with multi-organ involvement characterized by vascular endothelial growth factor (VEGF) overproduction. 1 Standard therapeutic strategy has not been well-established, and management is mainly derived from retrospective studies. For patients with isolated or limited numbers of bone lesions, radiation could be used. In contrast, systemic treatment, including melphalan, autologous stem cell transplantation and novel agents, is usually required for those who with disseminated bone marrow involvement. Despite continuing advances in the treatment of POEMS syndrome, there is no therapeutic consensus, thereby necessitating the development and evaluation of novel treatment. Early pharmacological studies have demonstrated that immunomodulatory effects of lenalidomide, including inhibition of cytokine production, which is the main driver of POEMS pathogenesis, could be achieved at low doses. 7 Our previous retrospective study showed impressive response of low dose lenalidomide (10 mg daily) plus dexamethasone in relapsed or refractory POEMS patients, achieving complete hematologic response of 33% and neurological response of 67%, 8 without either treatment-related death or any grade 3 or 4 toxicity.
These findings prompt us to conduct a phase II study to evaluate the response and safety of this regime in patients with newly diagnosed POEMS syndrome prospectively.
| M E TH ODS
This phase II, single-center, single-arm trial was conducted in Peking Union Medical College Hospital (Beijing, China) as registered in ClinicalTrials.gov (NCT01816620). All patients provided signed informed consent before study entry. The study was performed in accordance with the Declaration of Helsinki, with prior approval of the institutional review board and the ethics committee of the local hospital.
| Patients
Patient number was estimated based on Simon's two-stage design. were collected at the time of diagnosis, as described previously. 10, 11 Briefly, overall neuropathy limitation scale (ONLS) conducted by the same operator was used to assess neurologic disability, 12 as other clinical studies of POEMS syndrome. 6, 13 Laboratory studies included serum VEGF, protein electrophoresis, serum and urine immunofixation electrophoresis, and bone marrow examinations. Serum VEGF was measured with a human Quantikine ELISA Kit (normal < 600 pg/mL; R&D Systems, Minneapolis, Minnesota). VEGF concentration reduction was defined as (VEGF concentration at baseline -VEGF concentration after therapy)/VEGF concentration at baseline. 2 The estimated glomerular filtration rate (eGFR) was calculated using the Chronic Kidney Disease Epidemiology Collaboration equation.
14 Systolic pulmonary arterial pressure (sPAP) was estimated based on echocardiography, and pulmonary arterial hypertension (PAH) was defined as a sPAP 50 mm Hg. 15 All patients underwent 18 
F-FDG
Positron emission tomography-computed tomography (PET-CT) at baseline. 16 Pleural effusion and ascites were detected by the mediastinal window of computed tomography.
Patients were stratified into different risk categories. 
| Study design and treatment
Patients were administered low dose Rdex regimen (lenalidomide 10 mg, daily, d1-21; dexamethasone 40 mg, weekly, d1, 8, 15, 22), out of a 28-day cycle. Given the intrinsic thrombophilic tendency of POEMS patients and thrombotic risk of Rdex regime, 100 mg aspirin was added to all patients. Specific hematological and nonhematological toxicities required dose delays and/or modification were recorded. All the patients were followed up monthly for the first three months and every three months afterwards to evaluate response and safety. After the 12 cycles of Rdex therapy, patients were followed up every six months.
| Assessment
The primary end points were hematological and neurological responses, as detailed below. Patients were followed for disease progression and overall survival (OS) for up to three years after discontinuation, which is still ongoing. Safety data were collected until 30 days after the last dose of study drug, except for secondary primary malignancies (SPM) (which were assessed all along during follow-up). SPM was defined as any malignancy observed after Rdex treatment.
| Definition and evaluation of responses
If patients did not meet criteria for a measurable parameter, they were considered unevaluable for that parameter and noted as such.
Hematologic, serum VEGF, neurologic and renal response was performed at every follow-up. Ascites, pleural effusions and sPAP was assessed every 3 months through computed tomography and echocardiography. PET/CT response were evaluated 2 weeks after the end of the 12-cycle application of Rdex in patients with FDG avidity on a baseline PET scan.
| Hematologic response
Hematologic responses included complete response (CR H ), negative immunofixation of the serum and urine; and no CR H . 18 This dichotomized definition was used in our previous study 13 
| Neurologic response
We defined reduction of 1 score of ONLS as neurologic response (R N ). 10 
| 18 F-FDG PET/CT response
PET responses included, complete radiologic response (CR R ), which referred to initial FDG avidity on a baseline PET scan that disappears after therapy; partial radiologic response (PR R ), which referred to initial FDG avidity that was 50% improved after therapy. 
| Definition of progression/relapse

| Response
The details of hematologic, serum VEGF, neurologic and other clinical responses in 41 patients after Rdex therapy and at last follow-up were shown in Supporting Information. No statistically significant differences were observed among patients with different risk categories.
| Hematologic response (H-R)
Twenty-one patients (46%) achieved CR H , and the remaining patients (49%) remained at nonresponse status. Two cases of complete hematological response were noted during the follow-up after 12 cycles of therapy. There was no difference in VEGF, neurological and other clinical response between hematological CR and non-CR groups.
| Serum VEGF response (V-R)
Forty cases (98%) had elevated levels of serum VEGF at diagnosis. The mean VEGF reduction was 43% and 61%, at first month and after completion of therapy, respectively (Figure 1 ). The median value declined LI ET AL. 
| D ISC USSION
Treatment of POEMS syndrome is not standardized, although algorithm based on bone marrow involvement and the number of bone lesions has been proposed. In patients with isolated bone lesions and negative bone marrow examination, radiation is suggested. Otherwise, systemic therapy, especially autotransplant, is recommended. However, in the well-described Mayo series, only 26% were eligible to receive radiation as their primary therapy. Moreover, with the advance of imaging modality, extensive bone involvement has been identified in majority of the cases, limiting the use of radiation. 16 In terms of Intriguingly, no significant differences of responses and survivals were seen among patients with different baseline risk categories. This could be related to the remission of both severe kidney impairment and pulmonary hypertension after treatment, which are the main factors contributing to inferior outcomes. Indeed, our previous study demonstrated that renal response, if achieved, was associated with improved survival. 20 Moreover, lenalidomide, compared to other treatment, induced more rapid response. 20 This could also be true for pulmonary hypertension. In the retrospective French series, 4 of 5 patients with pulmonary hypertension had improvement after therapy.
These findings suggest that lenalidomide could be more beneficial for those who with organ dysfunction.
Regarding the safety profile, neither treatment-related death nor lenalidomide-related grade 3 or above adverse events was observed during therapy. The most common hematologic and nonhematologic toxicity were neutropenia and transaminase elevation, respectively. In contrast, in the French phase II trial, 2 of 27 (7%) developed lenalidomide-related grade 3 or 4 adverse events, which were predominantly hematologic. In the retrospective French series, 9 patients (45%) experienced at least one grade 3 or above adverse event attributed to lenalidomide. Of note, no significant bradycardia was observed in our study, while approximately 50% of patients treated with thalidomide developed sinus bradycardia in the recent Japan trial. 2 It is noteworthy that although POEMS patients are at increased risk of thromboembolism and lenalidomide-dexamethasone regime is thrombophilic, no thrombotic event was observed during our therapy, with the use of aspirin as thromboprophylaxis. This finding might be either related to lower dose of lenalidomide used in our study or features of Asian population, which indeed shows lower risk of thromboembolism in myeloma treated with thalidomide. 21, 22 Together, these results illustrated the favorable safety profile of our regime.
Last but not least, the advent of novel agents, herein lenalidomide, in POEMS therapy let us reconsider the role of autotransplant. For patients ineligible for autotransplant, which could be up to 50% of the cases in view of the multiple organ dysfunction, novel agents could still achieve impressive responses. It can also be used as the pretransplant induction agent to make further autotransplant feasible and safe. 13 Moreover, for those who eligible for autotransplant, the role of upfront treatment is debatable, as the scenario in multiple myeloma. POEMS patients are even younger, and have prolonged disease course. Therefore, a deep and sustained response after upfront novel agent treatment could let autotransplant be reserved as salvage therapy for patients at the time of relapse. This will be examined in our future follow-up.
This study has its limitations. First, this is a single-center trial with a small number of patients, but significant therapeutic response was
shown. These results could be the evidence to progress lenalidomide into phase III studies. Second, no control arm was designed, as steroid alone only has temporal benefit for POEMS patients. 23 Further studies are required to compare Rdex with other treatment options. Last, observation period is relatively short, which could be extended in further follow up, hoping to determine the long-term survival benefit of this regime.
In conclusion, the combination of low-dose lenalidomide and dexamethasone is active with high response rate and well tolerated with excellent safety profile for patients with newly diagnosed POEMS syndrome.
